Cargando…

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa

This study established the in vitro activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible Pseudomonas aeruginosa (CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility r...

Descripción completa

Detalles Bibliográficos
Autores principales: Teo, Jocelyn Qi-Min, Lim, Jie Chong, Tang, Cheng Yee, Lee, Shannon Jing-Yi, Tan, Si Hui, Sim, James Heng-Chiak, Ong, Rick Twee-Hee, Kwa, Andrea Lay-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885320/
https://www.ncbi.nlm.nih.gov/pubmed/33504661
http://dx.doi.org/10.1128/mSphere.01026-20
_version_ 1783651580639182848
author Teo, Jocelyn Qi-Min
Lim, Jie Chong
Tang, Cheng Yee
Lee, Shannon Jing-Yi
Tan, Si Hui
Sim, James Heng-Chiak
Ong, Rick Twee-Hee
Kwa, Andrea Lay-Hoon
author_facet Teo, Jocelyn Qi-Min
Lim, Jie Chong
Tang, Cheng Yee
Lee, Shannon Jing-Yi
Tan, Si Hui
Sim, James Heng-Chiak
Ong, Rick Twee-Hee
Kwa, Andrea Lay-Hoon
author_sort Teo, Jocelyn Qi-Min
collection PubMed
description This study established the in vitro activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible Pseudomonas aeruginosa (CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility rates were low, at 37.9%. Cross-resistance to ceftazidime/avibactam was observed, although susceptibility to the agent was slightly higher, at 41.0%. Whole-genome sequencing revealed that C/T resistance was largely mediated by the presence of horizontally acquired β-lactamases, especially metallo-β-lactamases. These were primarily disseminated in well-recognized high-risk clones belonging to sequence types (ST) 235, 308, and 179. C/T resistance was also observed in several non-carbapenemase-producing isolates, in which resistance was likely mediated by β-lactamases and, to a smaller extent, mutations in AmpC-related genes. There was no obvious mechanism of resistance observed in five isolates. The high C/T resistance highlights the limited utility of the agent as an empirical agent in our setting. Knowledge of local molecular epidemiology is crucial in determining the potential of therapy with novel agents. IMPORTANCE Pseudomonas aeruginosa infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel β-lactam/β-lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant P. aeruginosa infections. Our findings demonstrate geographical variation in C/T susceptibility owing to the distinct local molecular epidemiology. This study adds on to the growing knowledge of C/T resistance, particularly mutational resistance, and will aid in the design of future β-lactams and β-lactamase inhibitors. WGS proved to be a useful tool to understand the P. aeruginosa resistome and its contribution to emerging resistance in novel antimicrobial agents.
format Online
Article
Text
id pubmed-7885320
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-78853202021-02-19 Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa Teo, Jocelyn Qi-Min Lim, Jie Chong Tang, Cheng Yee Lee, Shannon Jing-Yi Tan, Si Hui Sim, James Heng-Chiak Ong, Rick Twee-Hee Kwa, Andrea Lay-Hoon mSphere Research Article This study established the in vitro activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible Pseudomonas aeruginosa (CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility rates were low, at 37.9%. Cross-resistance to ceftazidime/avibactam was observed, although susceptibility to the agent was slightly higher, at 41.0%. Whole-genome sequencing revealed that C/T resistance was largely mediated by the presence of horizontally acquired β-lactamases, especially metallo-β-lactamases. These were primarily disseminated in well-recognized high-risk clones belonging to sequence types (ST) 235, 308, and 179. C/T resistance was also observed in several non-carbapenemase-producing isolates, in which resistance was likely mediated by β-lactamases and, to a smaller extent, mutations in AmpC-related genes. There was no obvious mechanism of resistance observed in five isolates. The high C/T resistance highlights the limited utility of the agent as an empirical agent in our setting. Knowledge of local molecular epidemiology is crucial in determining the potential of therapy with novel agents. IMPORTANCE Pseudomonas aeruginosa infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel β-lactam/β-lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant P. aeruginosa infections. Our findings demonstrate geographical variation in C/T susceptibility owing to the distinct local molecular epidemiology. This study adds on to the growing knowledge of C/T resistance, particularly mutational resistance, and will aid in the design of future β-lactams and β-lactamase inhibitors. WGS proved to be a useful tool to understand the P. aeruginosa resistome and its contribution to emerging resistance in novel antimicrobial agents. American Society for Microbiology 2021-01-27 /pmc/articles/PMC7885320/ /pubmed/33504661 http://dx.doi.org/10.1128/mSphere.01026-20 Text en Copyright © 2021 Teo et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Teo, Jocelyn Qi-Min
Lim, Jie Chong
Tang, Cheng Yee
Lee, Shannon Jing-Yi
Tan, Si Hui
Sim, James Heng-Chiak
Ong, Rick Twee-Hee
Kwa, Andrea Lay-Hoon
Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
title Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
title_full Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
title_fullStr Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
title_full_unstemmed Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
title_short Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
title_sort ceftolozane/tazobactam resistance and mechanisms in carbapenem-nonsusceptible pseudomonas aeruginosa
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885320/
https://www.ncbi.nlm.nih.gov/pubmed/33504661
http://dx.doi.org/10.1128/mSphere.01026-20
work_keys_str_mv AT teojocelynqimin ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa
AT limjiechong ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa
AT tangchengyee ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa
AT leeshannonjingyi ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa
AT tansihui ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa
AT simjameshengchiak ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa
AT ongricktweehee ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa
AT kwaandrealayhoon ceftolozanetazobactamresistanceandmechanismsincarbapenemnonsusceptiblepseudomonasaeruginosa